Sugi Predict

Sugi Predict / Compounds / SCHEMBL16555403

SCHEMBL16555403

SCHEMBL16555403

Cc1c(S)ccc(F)c1C#N

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 3/20 0.43
▸ USP8 P40818 1/20 0.32
▸ USP7 Q93009 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ RECQL P46063 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ GAA P10253 1/20 0.31
▸ GFER P55789 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ ALDH1A1 P00352 3/20 0.31
▸ HPGD P15428 2/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ DRD2 P14416 1/20 0.30
▸ HTR2A P28223 1/20 0.30
▸ HRH1 P35367 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8090040 0.82 TRPV4 (0.39) TRPV4USP8USP7KDM4EGAA
SCHEMBL17192918 0.78 TRPV4 (0.37) TRPV4USP8USP7KDM4ETDP1
SCHEMBL16555586 0.78 TRPV4 (0.46) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL16122042 0.77 TRPV4 (0.41) TRPV4TDP1
SCHEMBL27401021 0.75 GRM6 (0.36) TRPV4KDM4ERECQLTDP1ALDH1A1
SCHEMBL28069805 0.75 TRPV4 (0.34) TRPV4USP8USP7KDM4EGAA
SCHEMBL286417 0.75 TRPV4 (0.34) TRPV4USP8USP7KDM4ETDP1
SCHEMBL30294701 0.75 TRPV4 (0.34) TRPV4USP8USP7KDM4ETDP1
SCHEMBL4323122 0.74 TRPV4 (0.48) TRPV4KDM4EGAAGFERMEN1
SCHEMBL31432707 0.72 LMNA (0.39) KDM4EGAAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49948-E1 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2024-04-30 — — US disclosed
CN-110372550-B Aryl ethers and their use 佩洛通治疗公司 2021-08-24 — — CN disclosed
EP-3417851-B1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS INC (US) 2020-07-22 — — EP disclosed
US-20200190031-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. (US) 2020-06-18 — — US disclosed
US-10597366-B2 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2020-03-24 — — US disclosed
EP-3417852-B1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS INC (US) 2020-02-19 — — EP disclosed
EP-3043784-B9 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS INC (US) 2019-11-20 — — EP disclosed
EP-3043784-B1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS INC (US) 2019-05-15 — — EP disclosed
US-20190119214-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. 2019-04-25 — — US disclosed
EP-3417851-A1 ARYL ETHERS AND USES THEREOF Peloton Therapeutics, Inc. (US) 2018-12-26 — — EP disclosed
US-10144711-B2 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2018-12-04 — — US disclosed
US-20180155279-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. 2018-06-07 — — US disclosed
US-9969689-B2 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2018-05-15 — — US disclosed
US-9908845-B2 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2018-03-06 — — US disclosed
US-9896418-B2 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2018-02-20 — — US disclosed
US-20170217891-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. 2017-08-03 — — US disclosed
US-20170217892-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. 2017-08-03 — — US disclosed
US-20160251307-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. (US) 2016-09-01 — — US disclosed
EP-3043784-A1 ARYL ETHERS AND USES THEREOF Peloton Therapeutics, Inc. (US) 2016-07-20 — — EP disclosed
WO-2015035223-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. (US) 2015-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155279-A1 ARYL ETHERS AND USES THEREOF HIF1AN, EGLN2, VHL TRPV4 4279/4885USP8 498/4885USP7 598/4885
US-20160251307-A1 ARYL ETHERS AND USES THEREOF HIF1AN, EGLN2, VHL TRPV4 4279/4885USP8 498/4885USP7 598/4885
US-20170217892-A1 ARYL ETHERS AND USES THEREOF HIF1AN, EGLN2, VHL TRPV4 4279/4885USP8 498/4885USP7 598/4885
US-20190119214-A1 ARYL ETHERS AND USES THEREOF HIF1AN, EGLN2, VHL TRPV4 4279/4885USP8 498/4885USP7 598/4885
US-20170217891-A1 ARYL ETHERS AND USES THEREOF HIF1AN, EGLN2, VHL TRPV4 4279/4885USP8 498/4885USP7 598/4885
US-20200190031-A1 ARYL ETHERS AND USES THEREOF HIF1AN, EGLN2, VHL TRPV4 4279/4885USP8 498/4885USP7 598/4885
US-10597366-B2 Aryl ethers and uses thereof HIF1AN, EGLN2, VHL TRPV4 4279/4885USP8 498/4885USP7 598/4885
US-10144711-B2 Aryl ethers and uses thereof HIF1AN, EGLN2, VHL TRPV4 4279/4885USP8 498/4885USP7 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.